2022.05.05
I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act
I-Mab today provided updates on its status under the Holding Foreign Companies Accountable Act.
Press Releases
2022.04.28
I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer
I-Mab announced today two key appointments of Mr. Richard Yeh as Chief Operating Officer and Dr. John Hayslip as Chief Medical Officer.
2022.03.31
I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment
I-Mab today announced that the Company’s key shareholders and its senior management team have voluntarily entered into a 180-days lock-up period commencing from March 31, 2022.
Media Reports
2022.02.03
Endpoints: I-Mab expands manufacturing for multiple myeloma antibody; Granules issued ‘minor observations’ after inspection
Read at Endpoints2021.07.09
FierceBiotech: I-Mab boards popular mRNA train with 2 biotech collaborations
Read at FierceBiotech2021.05.19
2021.5-Endpoints: #ASCO21: AbbVie-partnered Chinese biotech with first-in-class ambitions showcases early data on CD73 antibody
Read at EndpointsPartner News
2021.07.09
2021.06.29
2020.11.09